Organogenesis Holdings Inc.

Organogenesis Holdings Inc. (ORGO) is a regenerative medicine company focused on advanced wound care and surgical biologics that entered the public markets through its December 2018 de-SPAC merger with Avista Healthcare Public Acquisition Corp, a blank-check vehicle sponsored by Avista Capital Holdings. The company, headquartered in Canton, Massachusetts, has operated as a publicly traded entity on Nasdaq since that transaction closed, competing in the healthcare and medical technology sector. Its most recent SEC filing is a Form 10-Q submitted on August 7, 2025, covering quarterly financial results as an ongoing reporting issuer. Sign up at SpacDesk for full filing history, deal terms, and sponsor analytics on Organogenesis Holdings and hundreds of other de-SPAC companies.